Clinical Trial Update: Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Open-label extension study to assess safety and tolerability of LYC-30937-EC in active ulcerative colitis (Phase 2) has been terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• LYC-30937-EC

Snippet

Sponsor: Lycera Corp. | Conditions: Colitis, Ulcerative | Phase 2 | Status: TERMINATED | Results posted: 2019-03-27